RICHARD C CHERNY M.D. NPI 1659351484

NPI Details

Richard C Cherny, M.D. is a hematology and oncology internal medicine in East Syracuse, NY with 43 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Richard C Cherny, M.D. NPI is 1659351484. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY
Graduation Year:1983

The provider's business location address is:

5008 BRITTONFIELD PKWY
SUITE 700
EAST SYRACUSE, NY
ZIP 13057
Phone: (315) 472-7504
Fax: (315) 479-8639

The NPI 1659351484 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1561)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, pemetrexed, not otherwise specified, 10 mg (HCPCS:J9305)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg (HCPCS:Q5117)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg (HCPCS:Q5111)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Unclassified drugs (HCPCS:J3490)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Ferritin (blood protein) level (HCPCS:82728)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection, hydrocortisone sodium succinate, up to 100 mg (HCPCS:J1720)
• Ct scan of chest with contrast (HCPCS:71260)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Protein measurement, serum (HCPCS:84165)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Drawing of blood for a medical problem (HCPCS:99195)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Injection of drug or substance into vein (HCPCS:96374)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Ct scan of chest without contrast (HCPCS:71250)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Influenza vaccine split virus, preservative free (HCPCS:90662)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Magnesium level (HCPCS:83735)
• Injection, lorazepam, 2 mg (HCPCS:J2060)
• Total protein level, blood (HCPCS:84155)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Initial hospital inpatient care per day, typically 30 minutes (HCPCS:99221)
• Urea nitrogen level to assess kidney function, quantitative (HCPCS:84520)
• Blood creatinine level (HCPCS:82565)
• Phosphate level (HCPCS:84100)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Red blood cell sedimentation rate, to detect inflammation, non-automated (HCPCS:85651)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)

The enumeration date for this NPI number is 1/18/2006 and was last updated on 8/3/2018.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.